Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog)

E. J. Lee; K. R. Kim; S. K. Lim; H. C. Lee; D. I. Kim; S. H. Kim; K. B. Huh

doi:10.1530/eje.0.1310109

Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog)

E. J. Lee, K. R. Kim, S. K. Lim, H. C. Lee, D. I. Kim, S. H. Kim, K. B. Huh

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

Abstract

We present a 55-year-old female with a thyrotropin (TSH)-secreting pituitary adenoma who had been treated with somatostatin analog octreotide acetate (SMS 201-995) for 4 months. Subcutaneous injection of 100 μg octreotide acetate twice daily resulted in significant reduction of the TSH, thyroid hormone, and tumor size. During the treatment, there was no evidence of any side effects. We may conclude that octreotide acetate administration is an effective treatment in patients with TSH-secreting pituitary adenoma for suppressing TSH hypersecretion and reducing the size of the tumor.

Original language	English
Pages (from-to)	109-112
Number of pages	4
Journal	European Journal of Endocrinology
Volume	131
Issue number	1
DOIs	https://doi.org/10.1530/eje.0.1310109
Publication status	Published - 1994

All Science Journal Classification (ASJC) codes

Endocrinology, Diabetes and Metabolism
Endocrinology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1530/eje.0.1310109

Cite this

@article{8bc435b59a7847b28f136facbf8afdf0,

title = "Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog)",

abstract = "We present a 55-year-old female with a thyrotropin (TSH)-secreting pituitary adenoma who had been treated with somatostatin analog octreotide acetate (SMS 201-995) for 4 months. Subcutaneous injection of 100 μg octreotide acetate twice daily resulted in significant reduction of the TSH, thyroid hormone, and tumor size. During the treatment, there was no evidence of any side effects. We may conclude that octreotide acetate administration is an effective treatment in patients with TSH-secreting pituitary adenoma for suppressing TSH hypersecretion and reducing the size of the tumor.",

author = "Lee, {E. J.} and Kim, {K. R.} and Lim, {S. K.} and Lee, {H. C.} and Kim, {D. I.} and Kim, {S. H.} and Huh, {K. B.}",

year = "1994",

doi = "10.1530/eje.0.1310109",

language = "English",

volume = "131",

pages = "109--112",

journal = "European Journal of Endocrinology",

issn = "0804-4643",

publisher = "BioScientifica Ltd.",

number = "1",

}

TY - JOUR

T1 - Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog)

AU - Lee, E. J.

AU - Kim, K. R.

AU - Lim, S. K.

AU - Lee, H. C.

AU - Kim, D. I.

AU - Kim, S. H.

AU - Huh, K. B.

PY - 1994

Y1 - 1994

N2 - We present a 55-year-old female with a thyrotropin (TSH)-secreting pituitary adenoma who had been treated with somatostatin analog octreotide acetate (SMS 201-995) for 4 months. Subcutaneous injection of 100 μg octreotide acetate twice daily resulted in significant reduction of the TSH, thyroid hormone, and tumor size. During the treatment, there was no evidence of any side effects. We may conclude that octreotide acetate administration is an effective treatment in patients with TSH-secreting pituitary adenoma for suppressing TSH hypersecretion and reducing the size of the tumor.

AB - We present a 55-year-old female with a thyrotropin (TSH)-secreting pituitary adenoma who had been treated with somatostatin analog octreotide acetate (SMS 201-995) for 4 months. Subcutaneous injection of 100 μg octreotide acetate twice daily resulted in significant reduction of the TSH, thyroid hormone, and tumor size. During the treatment, there was no evidence of any side effects. We may conclude that octreotide acetate administration is an effective treatment in patients with TSH-secreting pituitary adenoma for suppressing TSH hypersecretion and reducing the size of the tumor.

UR - http://www.scopus.com/inward/record.url?scp=0028247380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028247380&partnerID=8YFLogxK

U2 - 10.1530/eje.0.1310109

DO - 10.1530/eje.0.1310109

M3 - Article

C2 - 8038902

AN - SCOPUS:0028247380

SN - 0804-4643

VL - 131

SP - 109

EP - 112

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

IS - 1

ER -

Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog)

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this